Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome.
Iron chelation therapy in patients with transfusion-dependent myelodysplastic syndrome.
复制标题
输血依赖性骨髓增生异常综合征患者的铁螯合疗法。
DOI：
10.1111/j.1537-2995.2012.03894.x
复制
发表时间：
2012
期刊：
影响因子：
2.9
通讯作者：
Field,JoshuaJ
中科院分区：
文献类型：
--
作者：
Mast,AlanE;Field,JoshuaJ
输血医学的实践挽救了病人的生命。输注红细胞（RBC）可增加重要组织血管床内的氧气。输注血小板和血浆可增强严重出血或有严重出血风险患者的止血效果。执行这些挽救生命的程序的一个经常被忽视的后果是输血对献血者和输血接受者的铁状态的影响。定期献血会导致许多献血者缺铁。1-3应预防献血者缺铁的发展，特别是在16至18岁的献血者中，这些献血者仍在进行认知发育。4，5当前供体管理的问题包括为不同的供体人口统计学群体定义适当的供体间隔，以允许在供体之间进行铁补充，并在目标供体群体中建立有效的铁替代治疗程序。六、七
The practice of transfusion medicine saves lives of patients. Transfusion of red blood cells (RBCs) enhances the oxygen available within the vascular beds of vital tissues. Transfusion of platelets and plasma enhances hemostasis in patients suffering from or at risk of severe hemorrhage. An often overlooked consequence of performing these lifesaving procedures is the impact that blood transfusion has on the iron status of both the blood donor and the transfusion recipient.Regular blood donation causes many donors to become iron deficient. 1–3 The development of iron deficiency in blood donors should be prevented and is of particular concern in 16-to 18-year-old donors that are continuing to undergo cognitive development. 4, 5 Current issues in donor management include defining the appropriate donation intervals for different donor demographic groups to allow for iron repletion between donations and establishing effective procedures for iron replacement therapy in targeted donor groups. 6, 7